key: cord-0982736-xcpb5u5l
authors: Prentice, Ralley E.; Al-Ani, Aysha H; Bond, Katherine; Johnson, Doug; Christensen, Britt
title: Letter to the Editor: Asymptomatic Screening for SARS CoV-2 prior to commencement of biologic therapies in patients with Inflammatory Bowel Disease - a potentially harmful practice.
date: 2020-08-27
journal: Dig Liver Dis
DOI: 10.1016/j.dld.2020.08.035
sha: 2b0d37282b56b1aeea9c5aab671fa67fbf6cad6d
doc_id: 982736
cord_uid: xcpb5u5l

nan

We read with interest the recent publication by Zingone et al "Screening for active COVID-19 infection and immunization status prior to biologic therapy in IBD patients at the time of the pandemic outbreak" 1 . They advocate for screening all patients with inflammatory bowel disease (IBD) for SARS CoV-2 prior to commencement of biologic agents with the use of both IgM and IgG antibodies and nasopharyngeal PCR testing, intending to identify both current infection with, and previous exposure to, the virus 1 . We argue that universal adoption of such a protocol warrants careful consideration and presently lacks adequate evidence.

For universal screening to be of benefit, we would expect the positive predictive value (PPV) of the test to be sufficient to differentiate infectious patients amongst an asymptomatic cohort, and for subsequent actions to improve individual or public health outcomes. It is difficult to justify how the aforementioned screening protocol prior to biologics would meet these requirements. Firstly, it is unclear whether IBD patients are more or less likely to develop asymptomatic COVID-19 when infected by SARS CoV-2. In addition, apart from those on high dose corticosteroids, IBD patients do not appear more likely to develop severe complications overall in comparison to patients without IBD 2,3 .

Secondly, preliminary data cautiously suggests that patients with immune mediated inflammatory diseases (IMIDs) on biologics may be less likely to become infected with SARS CoV-2, with lower rates of seropositivity when comparing similarly socially exposed IMID patients and controls 4, 5 . Whether this indeed reflects a lower rate of infection with SARS CoV-2, or alternatively lower rates of detectable antibody response, is unclear. In conclusion, the balance of accumulating evidence favours the use of biological therapies in those patients with IBD who otherwise require them on the basis of IBD severity, as opposed to deliberate avoidance for fear of adverse outcomes. We agree with Zingone that there is much to learn about COVID-19 infection in this patient population,

Screening for active COVID-19 infection and immunization status prior to biologic therapy in IBD patients at the time of the pandemic outbreak

Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting

But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

Evaluation of serological tests for SARS-CoV-2: Implications for serology testing in a low-prevalence setting

Care of the Patient with IBD Requiring Hospitalization During the COVID-19 Pandemic

Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. The Lancet Public Health. 2020. 8. National Center for Immunization and Respiratory Diseases (NCIRD) DoVD. Interim Guidelines for COVID-19 Antibody Testing in Clinical and Public Health Settings

Society Message on COVID-19. COVID-19 Clinical Insights for Our Community of Gastroenterologists and Gastroenterology Care Providers Published

Safely restarting GI endoscopy in the era of COVID-19